Loading...
•
Dec 31, 2023
Generation Bio Q4 2023 Earnings Report
Generation Bio reported fourth quarter and full year 2023 financial results and business highlights.
Key Takeaways
Generation Bio is focusing on advancing its cell-targeted lipid nanoparticle and immune-quiet DNA platforms, with a focus on in vivo programs for sickle cell disease, beta-thalassemia, and hemophilia A. The company's cash balance is expected to fund operations into the second half of 2027.
Developing ctLNP for in vivo T cell and hematopoietic stem cell programs.
Developing iqDNA for programs in hepatocytes and other cell types.
Cash, cash equivalents and marketable securities were $264.4 million as of December 31, 2023.
The company continues to believe that its cash, cash equivalents and marketable securities will fund its operating expenditures and capital expenditure requirements into the second half of 2027.
Generation Bio
Generation Bio
Generation Bio Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com